Sabra Health Care REIT Analyst Ratings
Sabra Health Care REIT Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/11/2023 | 12.63% | B of A Securities | $11 → $14 | Upgrades | Underperform → Neutral |
07/27/2023 | 4.59% | Berenberg | → $13 | Initiates Coverage On | → Hold |
07/14/2023 | 0.56% | Citigroup | $11 → $12.5 | Maintains | Neutral |
04/25/2023 | 4.59% | Barclays | $15 → $13 | Maintains | Equal-Weight |
04/20/2023 | -11.5% | Wells Fargo | → $11 | Initiates Coverage On | → Underweight |
04/19/2023 | -11.5% | Wells Fargo | → $11 | Initiates Coverage On | → Underweight |
04/12/2023 | 4.59% | Credit Suisse | → $13 | Reiterates | → Neutral |
03/29/2023 | 4.59% | Truist Securities | $14 → $13 | Maintains | Buy |
03/28/2023 | -15.53% | Citigroup | $13 → $10.5 | Maintains | Neutral |
12/13/2022 | — | JMP Securities | Downgrades | Market Outperform → Market Perform | |
11/14/2022 | 4.59% | B of A Securities | $15 → $13 | Downgrades | Neutral → Underperform |
10/10/2022 | 4.59% | Baird | → $13 | Downgrades | Outperform → Neutral |
06/30/2022 | 12.63% | Jefferies | $15 → $14 | Downgrades | Buy → Hold |
05/25/2022 | 20.68% | Mizuho | $16 → $15 | Upgrades | Neutral → Buy |
04/18/2022 | 12.63% | Barclays | $16 → $14 | Downgrades | Overweight → Equal-Weight |
04/04/2022 | 20.68% | Credit Suisse | $14 → $15 | Maintains | Neutral |
03/11/2022 | 20.68% | B of A Securities | → $15 | Upgrades | Underperform → Neutral |
02/23/2022 | 44.81% | Stifel | $21 → $18 | Maintains | Buy |
02/18/2022 | — | Keybanc | Initiates Coverage On | → Sector Weight | |
02/01/2022 | 12.63% | Credit Suisse | → $14 | Initiates Coverage On | → Neutral |
09/30/2021 | 44.81% | Truist Securities | → $18 | Upgrades | Hold → Buy |
09/13/2021 | 60.9% | JMP Securities | $24 → $20 | Maintains | Market Outperform |
05/21/2021 | 68.95% | BMO Capital | $20 → $21 | Upgrades | Market Perform → Outperform |
05/10/2021 | 68.95% | Stifel | $17 → $21 | Upgrades | Hold → Buy |
01/13/2021 | 60.9% | Jefferies | $17 → $20 | Upgrades | Hold → Buy |
01/08/2021 | 52.86% | BMO Capital | → $19 | Upgrades | Underperform → Market Perform |
12/03/2020 | 93.08% | JMP Securities | → $24 | Upgrades | Market Perform → Market Outperform |
09/02/2020 | 20.68% | Stifel | → $15 | Reinstates | → Hold |
06/23/2020 | 20.68% | Scotiabank | $12 → $15 | Upgrades | Sector Underperform → Sector Perform |
06/22/2020 | 12.63% | Wells Fargo | $13 → $14 | Maintains | Equal-Weight |
05/18/2020 | 20.68% | Berenberg | → $15 | Upgrades | Hold → Buy |
04/23/2020 | — | SunTrust Robinson Humphrey | Maintains | Hold | |
04/07/2020 | -19.55% | Citigroup | $20 → $10 | Maintains | Neutral |
03/26/2020 | -15.53% | Wells Fargo | $22 → $10.5 | Maintains | Equal-Weight |
02/26/2020 | 76.99% | Mizuho | → $22 | Upgrades | Neutral → Buy |
02/06/2020 | 101.13% | Barclays | $26 → $25 | Maintains | Overweight |
02/05/2020 | 76.99% | Berenberg | → $22 | Initiates Coverage On | → Hold |
12/20/2019 | 76.99% | Mizuho | → $22 | Initiates Coverage On | → Neutral |
12/18/2019 | — | Citigroup | Upgrades | Sell → Neutral | |
10/14/2019 | — | B of A Securities | Reinstates | → Neutral | |
09/27/2019 | 85.04% | JMP Securities | $22 → $23 | Maintains | Market Outperform |
09/23/2019 | 60.9% | Citigroup | $18 → $20 | Downgrades | Neutral → Sell |
09/03/2019 | 93.08% | Barclays | → $24 | Initiates Coverage On | → Overweight |
02/26/2019 | — | BMO Capital | Downgrades | Market Perform → Underperform | |
12/17/2018 | 52.86% | Wells Fargo | $23 → $19 | Maintains | Market Perform |
11/16/2018 | 68.95% | B of A Securities | $23 → $21 | Downgrades | Neutral → Underperform |
11/16/2018 | — | Raymond James | Downgrades | Outperform → Market Perform | |
11/13/2018 | 68.95% | Mizuho | → $21 | Downgrades | Buy → Neutral |
09/19/2018 | 93.08% | BMO Capital | → $24 | Initiates Coverage On | → Market Perform |
08/17/2018 | 93.08% | Raymond James | $22 → $24 | Maintains | Outperform |
日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
08/11/2023 | 12.63% | B of A 類證券 | 11 美元 → 14 美元 | 升級 | 表現不佳 → 中性 |
07/27/2023 | 4.59% | 貝倫貝格 | → 13 美元 | 啓動覆蓋開啓 | → 按住 |
07/14/2023 | 0.56% | 花旗集團 | 11 美元 → 12.5 美元 | 維護 | 中立 |
2023 年 4 月 25 日 | 4.59% | 巴克萊 | 15 美元 → 13 美元 | 維護 | 重量相等 |
04/20/2023 | -11.5% | 富國銀行 | → 11 美元 | 啓動覆蓋開啓 | → 體重不足 |
04/19/2023 | -11.5% | 富國銀行 | → 11 美元 | 啓動覆蓋開啓 | → 體重不足 |
2023 年 12 月 4 日 | 4.59% | 瑞士信貸 | → 13 美元 | 重申 | → 中立 |
03/29/2023 | 4.59% | 信託證券 | 14 美元 → 13 美元 | 維護 | 購買 |
03/28/2023 | -15.53% | 花旗集團 | 13 美元 → 10.5 美元 | 維護 | 中立 |
12/13/2022 | — | JMP 證券 | 降級 | 市場跑贏大盤 → 市場表現 | |
11/14/2022 | 4.59% | B of A 類證券 | 15 美元 → 13 美元 | 降級 | 中性 → 跑贏大盤 |
2022 年 10 月 10 日 | 4.59% | 貝爾德 | → 13 美元 | 降級 | 跑贏大盤 → 中性 |
06/30/2022 | 12.63% | 傑富瑞 | 15 美元 → 14 美元 | 降級 | 買入 → 持有 |
05/25/2022 | 20.68% | 瑞穗 | 16 美元 → 15 美元 | 升級 | 中性 → 買入 |
04/18/2022 | 12.63% | 巴克萊 | 16 美元 → 14 美元 | 降級 | 超重 → 重量相等 |
2022 年 4 月 4 日 | 20.68% | 瑞士信貸 | 14 美元 → 15 美元 | 維護 | 中立 |
03/11/2022 | 20.68% | B of A 類證券 | → 15 美元 | 升級 | 表現不佳 → 中性 |
2022 年 2 月 23 日 | 44.81% | Stifel | 21 美元 → 18 美元 | 維護 | 購買 |
2022 年 2 月 18 日 | — | Keybanc | 啓動覆蓋開啓 | → 行業權重 | |
2022 年 1 月 2 日 | 12.63% | 瑞士信貸 | → 14 美元 | 啓動覆蓋開啓 | → 中立 |
09/30/2021 | 44.81% | 信託證券 | → 18 美元 | 升級 | 持有 → 買入 |
09/13/2021 | 60.9% | JMP 證券 | 24 美元 → 20 美元 | 維護 | 市場表現跑贏大盤 |
05/21/2021 | 68.95% | BMO 資本 | 20 美元 → 21 美元 | 升級 | 市場表現 → 跑贏大盤 |
2021 年 10 月 5 日 | 68.95% | Stifel | 17 美元 → 21 美元 | 升級 | 持有 → 買入 |
2021 年 1 月 13 日 | 60.9% | 傑富瑞 | 17 美元 → 20 美元 | 升級 | 持有 → 買入 |
01/08/2021 | 52.86% | BMO 資本 | → 19 美元 | 升級 | 表現不佳 → 市場表現 |
2020 年 3 月 12 日 | 93.08% | JMP 證券 | → 24 美元 | 升級 | 市場表現 → 市場跑贏大盤 |
2020 年 2 月 9 日 | 20.68% | Stifel | → 15 美元 | 恢復 | → 按住 |
06/23/2020 | 20.68% | 豐業銀行 | 12 美元 → 15 美元 | 升級 | 板塊表現不佳 → 板塊表現 |
2020 年 6 月 22 日 | 12.63% | 富國銀行 | 13 美元 → 14 美元 | 維護 | 重量相等 |
2020 年 5 月 18 日 | 20.68% | 貝倫貝格 | → 15 美元 | 升級 | 持有 → 買入 |
04/23/2020 | — | SunTrust 羅賓遜漢弗萊 | 維護 | 保持 | |
2020 年 7 月 4 日 | -19.55% | 花旗集團 | 20 美元 → 10 美元 | 維護 | 中立 |
2020 年 3 月 26 日 | -15.53% | 富國銀行 | 22 美元 → 10.5 美元 | 維護 | 重量相等 |
02/26/2020 | 76.99% | 瑞穗 | → 22 美元 | 升級 | 中性 → 買入 |
02/06/2020 | 101.13% | 巴克萊 | 26 美元 → 25 美元 | 維護 | 超重 |
02/05/2020 | 76.99% | 貝倫貝格 | → 22 美元 | 啓動覆蓋開啓 | → 按住 |
12/20/2019 | 76.99% | 瑞穗 | → 22 美元 | 啓動覆蓋開啓 | → 中立 |
2019 年 12 月 18 日 | — | 花旗集團 | 升級 | 賣出 → 中立 | |
2019 年 10 月 14 日 | — | B of A 類證券 | 恢復 | → 中立 | |
09/27/2019 | 85.04% | JMP 證券 | 22 美元 → 23 美元 | 維護 | 市場表現跑贏大盤 |
2019 年 9 月 23 日 | 60.9% | 花旗集團 | 18 美元 → 20 美元 | 降級 | 中性 → 賣出 |
2019 年 3 月 9 日 | 93.08% | 巴克萊 | → 24 美元 | 啓動覆蓋開啓 | → 超重 |
2019 年 2 月 26 日 | — | BMO 資本 | 降級 | 市場表現 → 跑贏大盤 | |
12/17/2018 | 52.86% | 富國銀行 | 23 美元 → 19 美元 | 維護 | 市場表現 |
11/16/2018 | 68.95% | B of A 類證券 | 23 美元 → 21 美元 | 降級 | 中性 → 跑贏大盤 |
11/16/2018 | — | 雷蒙德·詹姆 | 降級 | 跑贏大盤 → 市場表現 | |
11/13/2018 | 68.95% | 瑞穗 | → 21 美元 | 降級 | 買入 → 中性 |
09/19/2018 | 93.08% | BMO 資本 | → 24 美元 | 啓動覆蓋開啓 | → 市場表現 |
08/17/2018 | 93.08% | 雷蒙德·詹姆 | 22 美元 → 24 美元 | 維護 | 跑贏大盤 |
What is the target price for Sabra Health Care REIT (SBRA)?
Sabra Health Care REIT(SBRA)的目標價格是多少?
The latest price target for Sabra Health Care REIT (NASDAQ: SBRA) was reported by B of A Securities on August 11, 2023. The analyst firm set a price target for $14.00 expecting SBRA to rise to within 12 months (a possible 12.63% upside). 12 analyst firms have reported ratings in the last year.
A Securities於2023年8月11日公佈了Sabra Health Care REIT(納斯達克股票代碼:SBRA)的最新目標股價。這家分析公司將目標股價定爲14.00美元,預計SBRA將在12個月內升至12個月內(可能上漲12.63%)。去年有12家分析公司公佈了評級。
What is the most recent analyst rating for Sabra Health Care REIT (SBRA)?
分析師對Sabra Health Care REIT(SBRA)的最新評級是多少?
The latest analyst rating for Sabra Health Care REIT (NASDAQ: SBRA) was provided by B of A Securities, and Sabra Health Care REIT upgraded their neutral rating.
Sabra Health Care REIT(納斯達克股票代碼:SBRA)的最新分析師評級由B of A Securities提供,Sabra Health Care REIT上調了中性評級。
When is the next analyst rating going to be posted or updated for Sabra Health Care REIT (SBRA)?
Sabra Health Care REIT(SBRA)的下一個分析師評級何時公佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sabra Health Care REIT, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sabra Health Care REIT was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與Sabra Health Care REIT的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月進行一次評級,因此每家公司每年應該獲得4個評級。Sabra Health Care REIT的最後一次評級是在2023年8月11日提交的,因此您應該預計下一個評級將在2024年8月11日左右公佈。
Is the Analyst Rating Sabra Health Care REIT (SBRA) correct?
分析師對Sabra Health Care REIT(SBRA)的評級正確嗎?
While ratings are subjective and will change, the latest Sabra Health Care REIT (SBRA) rating was a upgraded with a price target of $11.00 to $14.00. The current price Sabra Health Care REIT (SBRA) is trading at is $12.43, which is within the analyst's predicted range.
儘管評級是主觀的,將會發生變化,但最新的Sabra Health Care REIT(SBRA)評級已上調,目標股價爲11.00美元至14.00美元。Sabra Health Care REIT(SBRA)目前的交易價格爲12.43美元,在分析師的預測區間內。